methyl 3-((tert-butoxycarbonyl)amino)-2-methylpropanoate | 182486-16-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 3-((tert-butoxycarbonyl)amino)-2-methylpropanoate
• 英文别名: methyl 2-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
• CAS: 182486-16-4
• 化学式: C₁₀H₁₉NO₄
• 分子量: 217.265
• InChiKey: JZHNQALXNGWKCG-UHFFFAOYSA-N

物化性质

• 沸点：
  302.8±25.0 °C(Predicted)
• 密度：
  1.035±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 3-((tert-butoxycarbonyl)amino)-2-methylpropanoate 生成 (R)-3-(Boc-氨基)异丁酸
  参考文献：
  名称：

  Total Synthesis of Cryptophycins via a Chemoenzymatic Approach

  摘要：

  A highly convergent synthesis of cryptophycins in their enantiomerically-pure forms was achieved. Our strategy consists of the synthesis of the two units 3 and 4 and linking them together to form the macrocyclic ring. The upper unit 3 was prepared from 10 in four steps, and the lower unit 4 was prepared from 20 in three steps. Enantioselective biocatalytic methodology was used to prepare the requisite chiral building blocks, (R)-11 and (R)-19. The stereochemical versatility of this synthetic approach is demonstrated by the synthesis of cryptophycin A and the four diastereomers of cryptophycin C.

  DOI：

  10.1021/jo960972i
• 作为产物：
  描述：

  2-(溴甲基)丙烯酸甲酯 在 palladium 10% on activated carbon 、 氢气 、 scandium tris(trifluoromethanesulfonate) 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成 methyl 3-((tert-butoxycarbonyl)amino)-2-methylpropanoate
  参考文献：
  名称：

  Synthesis of enantiopure β2-homoalanine derivatives via rhodium catalyzed asymmetric hydrogenation

  摘要：

  The stereoselective synthesis of chiral beta(2)-homoalanine derivatives with 99% ee by the Rh-catalyzed enantioselective hydrogenation of prochiral 2-aminomethyl acrylates is described. The subsequent transformation to chiral 3-amino-2-methylpropanols is also demonstrated. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2013.02.011

文献信息

• Arylethynyl derivatives
  申请人：Green Luke

  公开号：US20110251169A1

  公开（公告）日：2011-10-13

  The present invention relates to ethynyl compounds of formula I wherein R1, R2, R2′, R3, R3′, R4, R4′, U, V, W, Y, m, and n are as defined herein and to a pharmaceutically acceptable acid addition salts, to a racemic mixtures, or to its corresponding enantiomers and/or optical isomers and/or stereoisomers thereof. Compounds of formula I are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

  本发明涉及式I的乙炔基化合物，其中R1、R2、R2′、R3、R3′、R4、R4′、U、V、W、Y、m和n如本文所述，以及药用可接受的酸加成盐，或其对映体和/或光学异构体和/或立体异构体的相应外消旋混合物。式I的化合物是代谢型谷氨酸受体5亚型（mGluR5）的变构调节剂。
• Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases
  申请人：——

  公开号：US20030229084A1

  公开（公告）日：2003-12-11

  The present application describes novel barbituric acid derivatives of formula I: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R 1 , R 2 , R 3 , R 4 , R 5 , n, W, U, X, Y, Z, U a , X a , Y a , and Z a are defined in the present specification, which are useful as TNF-&agr; converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.

  本申请描述了式I的新型巴比妥酸衍生物： 1 或其药用可接受的盐或前药形式，其中A、B、L、R 1 、R 2 、R 3 、R 4 、R 5 、n、W、U、X、Y、Z、U a 、X a 、Y a 和Z a 在本规范中定义，这些衍生物可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。
• [EN] NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE<br/>[FR] NOUVEAUX COMPOSÉS ET CONJUGUÉS DE CRYPTOPHYCINE, LEUR PRÉPARATION ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI SA

  公开号：WO2017076998A1

  公开（公告）日：2017-05-11

  The present invention relates to cryptophycin compounds of formula (I). The invention also relates to cryptophycin payloads, to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The invention also relates to the process for preparing these conjugates.

  本发明涉及公式（I）的隐藻素化合物。该发明还涉及隐藻素有效载荷、隐藻素偶联物、含有它们的组合物及其治疗用途，尤其是作为抗癌剂。该发明还涉及制备这些偶联物的过程。
• [EN] ARYLETHYNYL DERIVATIVES<br/>[FR] DÉRIVÉS D'ARYLÉTHYNYLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011128279A1

  公开（公告）日：2011-10-20

  The present invention relates to ethynyl derivatives of formula (I) as allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). The variables in formula (I) are defined in the specification.

  本发明涉及式(I)的乙炔衍生物，作为代谢型谷氨酸受体亚型5（mGluR5）的别构调节剂。式(I)中的变量在说明书中有定义。
• [EN] PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLO[2,3-B]PYRAZINE-7-CARBOXAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE JAK ET SYK
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011144585A1

  公开（公告）日：2011-11-24

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula (I), wherein the variables Q and R, R2, and R3 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式（I）的新型吡咯吡嗪衍生物，其中变量Q和R，R2和R3如本文所述定义，其抑制JAK和SYK并且适用于治疗自身免疫和炎症性疾病。